Stock vs Stock Comparison

AbbVie Inc. vs Abbott Laboratories

ABBV wins the Tale of the Tape 5–4.

ABBV$217.13
ABT$86.99

🏆 Tale of the Tape

54
ABBVABT
6.9%Profitability (Net Margin)14.7%
106.2xValuation (P/E)24.0x
8.3%Efficiency (ROIC)10.1%
7/9Health (Piotroski F)5/9
2.0Safety (Altman Z)4.9
8.6%Growth (Rev YoY)5.7%
0.61Risk (Sharpe 1Y)-1.05
-42.50xBalance Sheet (D/E)0.64x
4.23%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.213
252-Day Correlation
0.224
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricABBVABT
Market Cap$384.7B$149.1B
P/E Ratio106.2x24.0x
Forward P/E13.4x14.1x
P/B-57.80x2.86x
Dividend Yield3.18%2.94%
Beta0.300.65

Quantitative Metrics

MetricABBVABT
DCF Fair Value$126.26$57.20
DCF Upside-38.9%-43.2%
Piotroski F7/95/9
Altman Z2.014.87
Beneish M-2.87-2.53
FCF Yield4.23%4.21%
Net Debt/EBITDA3.0x0.1x
ROIC8.3%10.1%
WACC7.4%9.4%
ROIC – WACC0.8pp0.7pp
Gross Margin70.2%56.4%
Net Margin6.9%14.7%
Rev Growth YoY8.6%5.7%
Sharpe (1Y)0.61-1.05
Max Drawdown 3Y
FCF Payout Ratio65%56%

ABBV Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ABBV vs ABT: Head-to-Head Analysis

AbbVie Inc. (ABBV) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ABBV generates a return on invested capital (ROIC) of 8.3% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ABBV and ABT is 0.213, indicating low correlation, making them an effective diversification pair in a portfolio context.

ABBV appears in 38 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ABBV or ABT?

Our quantitative analysis compares ABBV and ABT across nine fundamental dimensions. ABBV wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ABBV and ABT correlated?

The 252-day correlation between ABBV and ABT is 0.213. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.